Navigation Links
Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007
Date:2/13/2008

ting activities:

Depreciation and amortization 34,159 27,496

Amortization of premiums on investments, net

of accretion of discounts 4,576 3,204

Stock-based compensation charges 19,651 23,723

Stock option income tax benefits 2,596 191

Excess tax benefit from employee stock options (14,606) (9,187)

Loss on disposal of property and equipment 201 99

Impairment of fixed assets 502 -

Changes in assets and liabilities:

Accounts receivable (16,180) 6,544

Inventories 3,588 (7,798)

Prepaid expenses (6,141) (595)

Other current assets (2,307) 1,683

Other long-term assets (1,131) (2,147)

Accounts payable (1,818) (471)

Accrued salaries and employee benefits 4,273 2,063

Other accrued expenses 679 (27)

Income tax payable (397) 9,970

Deferred revenue 2,855 (7,516)

Deferred income tax (7,621) (6,559)

Deferred rent (118) (112)

Deferred compensation plan liabilities 683 961

Net cash provided by operating activities 109,584 101,020

Investing activities:

Proceeds from sales and maturities of

short-term investments 140,988 132,657

Purchases of short-term investments (298,824)
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Carl Hull Named President and Chief Operating Officer of Gen-Probe
2. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
3. Gen-Probe to Webcast Three Upcoming Presentations
4. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
5. Gen-Probe to Webcast Presentation at Bank of Americas 37th Annual Investment Conference
6. Imagenetix Inc. Reports Third Fiscal Quarter Results
7. China-Biotics, Inc. Reports Third Quarter 2008 Financial Results
8. Maxygen Reports Fourth Quarter and Year End 2007 Financial Results
9. Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007
10. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
11. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -- PharmaBoardroom,s new report, , Healthcare ... for free download , digs deep into this vibrant ... the sector today. One area where ... developing a homegrown pharmaceutical manufacturing base, even if the government,s ... way off. A cursory comparison with neighboring Morocco ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 ... pilot study of mazindol in children with attention deficit/hyperactivity ... in December 2014 . The paper, ... with attention deficit/hyperactivity disorder" ( Konofal et al, ... 1;8:2321-2332. eCollection 2014 ) shows that mazindol might ...
(Date:12/22/2014)... RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), a ... of autologous cell therapies, announced today the publication of ... conjunction with co-authors from Kyoto University and the University ... clinical research using dermal sheath cup (DSC) cells to ... paper entitled " Hair Follicle Dermal Stem Cells Regenerate ...
(Date:12/22/2014)... , Dec. 22, 2014  ( www.competitivehealth.com ) ... an online medical bill review and advocacy service, has ... the FREE WellCard Savings discount health services marketplace. ... that was more than they expected to pay. As ... health care costs, WellCard Savings is pleased to offer ...
Breaking Biology Technology:PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2
... LA JOLLA, Calif., Jan. 17, 2012  Synthetic Genomics Inc. ... solutions to solve a wide range of global challenges, ... Vice President for Nutritional Products. Stagnitti is a proven ... translating these into high value food and nutritional products ...
... Jan. 17, 2012 Reliv International, Inc. (NASDAQ: ... of LunaRich™, an exclusive soy powder developed at the Missouri ... of its nutritional supplements and will reveal that product at ... "Biotechnology is vital to Missouri,s economic future," said ...
... Inc. (NASDAQ: VVUS ) today announced that ... The Journal of Sexual Medicine (JSM), a peer-reviewed ... randomized, placebo-controlled, phase 3 study evaluating the safety and ... by the Food and Drug Administration (FDA) for the ...
Cached Biology Technology:Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program 2Reliv and Soy Labs Launch LunaRich, a Healthier Soy 2Reliv and Soy Labs Launch LunaRich, a Healthier Soy 3Reliv and Soy Labs Launch LunaRich, a Healthier Soy 4REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function 2REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function 3REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function 4REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function 5REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function 6
(Date:12/17/2014)... -- Automation is fundamentally transforming the travel experience and ... borders. Over the past decade, ePassports, biometric readers, ... to self process through border control via eGates ... increasing number of airports, seaports, and land borders ... Maxine Most , Principal at Acuity Market ...
(Date:12/11/2014)... 2014  Data Sciences International (DSI), the global ... new series of digital telemetry implants to meet ... series, part of the PhysioTel™ Digital platform, was ... physiologic data when incorporating functional endpoints into repeat-dose ... toxicology studies has evolved from short ECG strips ...
(Date:12/10/2014)... Dec. 08, 2014 Research and Markets ... of the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration ... as rural banking and upgradation of the driver,s ... in the market. Besides the aforementioned projects, biometrics ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... aimed at preventing cervical cancer is nearly 100 percent effective ... for most cases of cervical cancer. Results of a nationwide ... 9 issue of the New England Journal of Medicine. , ... deaths in women worldwide, resulting in nearly half a million ...
... helping to build a compelling case for oncolytic ... many cancers. , Reovirus, a non-pathogenic ... has shown powerful anti-cancer activity against cultured tumor ... trials. Oncolytics' proprietary reovirus formulation, Reolysin®, is active ...
... Universitat Autònoma de Barcelona, in cooperation with the animal ... model which faithfully reproduces the characteristics of dog’s skin ... various lines of research related to skin biology and ... The basic structure of skin consists of an external ...
Cached Biology News:Study shows continued success for new HPV vaccine against virus responsible for cervical cancer 2Dealing deadly cancers a knockout punch 2Dealing deadly cancers a knockout punch 3
Human M-CSF...
Human Serpin B5/Maspin Affinity Purified Polyclonal Ab...
... and S.J. Allen (1995) This ... world authorities on current issues relating to ... Several major advances have been made recently ... disease. Topics include molecular neuropathology through clinical ...
Normal human serum, single donor...
Biology Products: